市場調査レポート

商品コード

1792350

スタチン市場レポート：タイプ別、治療領域別、薬剤クラス別、用途別、流通別、地域別、2025～2033年

Statin Market Report by Type, Therapeutic Area, Drug Class, Application, Distribution, and Region 2025-2033

出版日: 2025年08月01日
発行: IMARC
ページ情報: 英文 143 Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF & Excel (Single User License)

USD 2,999 444,331円

レポートPDFおよびExcelを1名のみがご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピー&ペースト、印刷はできません。

PDF & Excel (5 User License)

USD 3,999 592,491円

レポートPDFおよびExcelを同一企業内の5名様までがご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピー&ペーストはできませんが、印刷は5部まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Corporate License)

USD 4,999 740,651円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピー&ペーストは可能ですが、事前にIMARC Services Private Limited社の許可が必要です。PDFおよびExcelの印刷回数に制限はありません。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=148.16円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

スタチンの世界市場規模は2024年に159億米ドルに達しました。今後、IMARC Groupでは、2033年に同市場は203億米ドルに達し、2025～2033年の成長率（CAGR）は2.74％になると予測しています。同市場は、世界の心血管疾患と高コレステロール血症の有病率の増加、ヘルスケアインフラの拡大、コレステロール低下薬への保険適用が可能であることなどが、全世界の需要を後押ししており、着実な成長を遂げています。

スタチン市場分析

市場の成長と規模世界市場は、心血管疾患の有病率の増加を主要因として大きな成長を遂げています。コレステロール低下薬に対する需要の高まりとともに、心臓の健康を管理する効果的な治療に対する認識とニーズの高まりを反映して、市場規模は拡大しています。
技術の進歩：特に個別化医療のセグメントにおける技術開発が、スタチン市場に革命をもたらしています。ゲノミクスとバイオインフォマティクスの進歩は、より個別化された治療アプローチを可能にし、スタチンの有効性を向上させ、副作用のリスクを低減しています。
産業の用途：スタチンは主に、LDLコレステロール値を低下させることによる心血管疾患の予防と治療のためにヘルスケア産業で使用されています。その用途は、特に心臓疾患のリスクが高い人々における心臓の健康管理に不可欠となっています。
主要市場動向：スタチン市場の顕著な動向は、個人の遺伝子プロファイルに合わせて治療を行う精密医療へのシフトです。さらに、予防ヘルスケア対策への注目が高まっており、これが心血管疾患の予防薬としてのスタチン需要の原動力となっています。
地理的動向：スタチンの需要は、高齢化が進み、心臓病の生活習慣関連危険因子が蔓延している地域で特に高いです。北米のや欧州のなどの開発地域が現在市場を独占しているが、新興経済諸国では健康意識の高まりやヘルスケアインフラの改善により需要が拡大しています。
競合情勢：世界市場には複数の主要参入企業が存在し、技術革新、製品開拓、マーケティング戦略によって競争が繰り広げられています。また、スタチン療法のアクセシビリティと有効性を高めるため、製薬企業とヘルスケアプロバイダとのコラボレーションも見られます。
課題と機会：市場における大きな課題の一つは、患者のコンプライアンスに影響を及ぼす可能性のある、スタチン使用に伴う副作用への対応です。しかし、この課題は副作用の少ない新しいスタチン製剤を開発する好機でもあります。さらに、世界の心血管疾患の発生率の増加は、市場拡大の大きな機会となります。

スタチン市場の動向

心血管疾患の有病率の増加

スタチンのコレステロール低下作用は、心血管疾患（CVD）の管理・予防治療に役立っています。しかし、このような医療費の増加は、高コレステロール血症などの危険因子に対する予防的な意識と管理の高まりにつながっています。その結果、この種の製品の市場が拡大しています。その結果、患者数の増加や一般的な予防医療への関心の高まりにより、スタチンに対するニーズは驚異的に高まっています。高齢者の数が増加し、生活習慣に関連した心臓病の危険因子を持つ地域社会では、スタチンは心血管治療の重要な一部となっています。

個別化医療の進歩

個別化医療あるいは精密医療は、スタチンに対する反応性に関して遺伝子型を調べることによって、それぞれの患者の特性に合った治療をデザインすることを目的としています。さらに、遺伝子変異がスタチンに対する効果や副作用のリスクを変化させる可能性があることが研究により明らかになっています。その結果、患者を個別に扱う傾向が強まり、そのたびにスタチン投薬の最適化がさらに洗練されています。前述とは別に、ヘルスケアにおけるゲノミクスとバイオインフォマティクスの融合が、開発の最も重要な要素であることは間違いないです。

政府の取り組みとヘルスケア施策

政府のイニシアティブと医療施策は、国際市場を広範囲に支配しています。世界中のさまざまな政府が、増加する心臓病を予防するための施策やプログラムを通じて行動を起こしています。これらのプログラムでは、コレステロールの管理に関する規制が頻繁に出され、最初の治療としてスタチンの使用が推奨されています。さらに、政府だけでなくヘルスケア機関も予防措置の重要性を強調することが多く、心臓病が発生してから治療するよりも予防することの有効性を認識しています。このような関心の変化により、コレステロールコントロールの重要性を強調する情報キャンペーンへの投資が増加しており、これがスタチンの需要を牽引しています。また、国内外の治療ガイドラインでスタチンが推奨されていることも、心臓の健康管理におけるこれらの薬剤の象徴的な役割を示しており、臨床現場での使用を後押ししています。

北米
- 米国
- カナダ
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- ロシア
- その他
アジア太平洋
- 中国
- 日本
- インド
- 韓国
- オーストラリア
- インドネシア
- その他
ラテンアメリカ
- ブラジル
- メキシコ
- その他
中東・アフリカ
- 市場内訳：国別

第12章 SWOT分析

概要
強み
弱み
機会
脅威

第13章バリューチェーン分析

第14章ポーターのファイブフォース分析

概要
買い手の交渉力
供給企業の交渉力
競合の程度
新規参入業者の脅威
代替品の脅威

第15章価格指標

第16章競合情勢

市場構造
主要企業
主要企業のプロファイル
- Abbott
- AstraZeneca
- Aurobindo Pharma
- Biocon
- GlaxoSmithKline
- Merck & Co.
- Novartis
- Pfizer

図表

List of Figures

Figure 1: Global: Statin Market: Major Drivers and Challenges
Figure 2: Global: Statin Market: Sales Value (in Billion USD), 2019-2024
Figure 3: Global: Statin Market: Breakup by Type (in %), 2024
Figure 4: Global: Statin Market: Breakup by Therapeutic Area (in %), 2024
Figure 5: Global: Statin Market: Breakup by Drug Class (in %), 2024
Figure 6: Global: Statin Market: Breakup by Application (in %), 2024
Figure 7: Global: Statin Market: Breakup by Distribution (in %), 2024
Figure 8: Global: Statin Market: Breakup by Region (in %), 2024
Figure 9: Global: Statin Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 10: Global: Statin (Synthetic Statins) Market: Sales Value (in Million USD), 2019 & 2024
Figure 11: Global: Statin (Synthetic Statins) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 12: Global: Statin (Natural Statins) Market: Sales Value (in Million USD), 2019 & 2024
Figure 13: Global: Statin (Natural Statins) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 14: Global: Statin (Cardiovascular Disorders) Market: Sales Value (in Million USD), 2019 & 2024
Figure 15: Global: Statin (Cardiovascular Disorders) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 16: Global: Statin (Obesity) Market: Sales Value (in Million USD), 2019 & 2024
Figure 17: Global: Statin (Obesity) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 18: Global: Statin (Inflammatory disorders) Market: Sales Value (in Million USD), 2019 & 2024
Figure 19: Global: Statin (Inflammatory disorders) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 20: Global: Statin (Other Therapeutic Areas) Market: Sales Value (in Million USD), 2019 & 2024
Figure 21: Global: Statin (Other Therapeutic Areas) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 22: Global: Statin (Atorvastatin) Market: Sales Value (in Million USD), 2019 & 2024
Figure 23: Global: Statin (Atorvastatin) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 24: Global: Statin (Fluvastatin) Market: Sales Value (in Million USD), 2019 & 2024
Figure 25: Global: Statin (Fluvastatin) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 26: Global: Statin (Lovastatin) Market: Sales Value (in Million USD), 2019 & 2024
Figure 27: Global: Statin (Lovastatin) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 28: Global: Statin (Pravastatin) Market: Sales Value (in Million USD), 2019 & 2024
Figure 29: Global: Statin (Pravastatin) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 30: Global: Statin (Simvastatin) Market: Sales Value (in Million USD), 2019 & 2024
Figure 31: Global: Statin (Simvastatin) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 32: Global: Statin (Other Drug Classes) Market: Sales Value (in Million USD), 2019 & 2024
Figure 33: Global: Statin (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 34: Global: Statin (Dyslipidemia) Market: Sales Value (in Million USD), 2019 & 2024
Figure 35: Global: Statin (Dyslipidemia) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 36: Global: Statin (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
Figure 37: Global: Statin (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 38: Global: Statin (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
Figure 39: Global: Statin (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 40: Global: Statin (Clinics) Market: Sales Value (in Million USD), 2019 & 2024
Figure 41: Global: Statin (Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 42: Global: Statin (Others) Market: Sales Value (in Million USD), 2019 & 2024
Figure 43: Global: Statin (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 44: North America: Statin Market: Sales Value (in Million USD), 2019 & 2024
Figure 45: North America: Statin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 46: United States: Statin Market: Sales Value (in Million USD), 2019 & 2024
Figure 47: United States: Statin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 48: Canada: Statin Market: Sales Value (in Million USD), 2019 & 2024
Figure 49: Canada: Statin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 50: Asia Pacific: Statin Market: Sales Value (in Million USD), 2019 & 2024
Figure 51: Asia Pacific: Statin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 52: China: Statin Market: Sales Value (in Million USD), 2019 & 2024
Figure 53: China: Statin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 54: Japan: Statin Market: Sales Value (in Million USD), 2019 & 2024
Figure 55: Japan: Statin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 56: India: Statin Market: Sales Value (in Million USD), 2019 & 2024
Figure 57: India: Statin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 58: South Korea: Statin Market: Sales Value (in Million USD), 2019 & 2024
Figure 59: South Korea: Statin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 60: Australia: Statin Market: Sales Value (in Million USD), 2019 & 2024
Figure 61: Australia: Statin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 62: Indonesia: Statin Market: Sales Value (in Million USD), 2019 & 2024
Figure 63: Indonesia: Statin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 64: Others: Statin Market: Sales Value (in Million USD), 2019 & 2024
Figure 65: Others: Statin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 66: Europe: Statin Market: Sales Value (in Million USD), 2019 & 2024
Figure 67: Europe: Statin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 68: Germany: Statin Market: Sales Value (in Million USD), 2019 & 2024
Figure 69: Germany: Statin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 70: France: Statin Market: Sales Value (in Million USD), 2019 & 2024
Figure 71: France: Statin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 72: United Kingdom: Statin Market: Sales Value (in Million USD), 2019 & 2024
Figure 73: United Kingdom: Statin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 74: Italy: Statin Market: Sales Value (in Million USD), 2019 & 2024
Figure 75: Italy: Statin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 76: Spain: Statin Market: Sales Value (in Million USD), 2019 & 2024
Figure 77: Spain: Statin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 78: Russia: Statin Market: Sales Value (in Million USD), 2019 & 2024
Figure 79: Russia: Statin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 80: Others: Statin Market: Sales Value (in Million USD), 2019 & 2024
Figure 81: Others: Statin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 82: Latin America: Statin Market: Sales Value (in Million USD), 2019 & 2024
Figure 83: Latin America: Statin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 84: Brazil: Statin Market: Sales Value (in Million USD), 2019 & 2024
Figure 85: Brazil: Statin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 86: Mexico: Statin Market: Sales Value (in Million USD), 2019 & 2024
Figure 87: Mexico: Statin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 88: Others: Statin Market: Sales Value (in Million USD), 2019 & 2024
Figure 89: Others: Statin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 90: Middle East and Africa: Statin Market: Sales Value (in Million USD), 2019 & 2024
Figure 91: Middle East and Africa: Statin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 92: Global: Statin Industry: SWOT Analysis
Figure 93: Global: Statin Industry: Value Chain Analysis
Figure 94: Global: Statin Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Statin Market: Key Industry Highlights, 2024 and 2033
Table 2: Global: Statin Market Forecast: Breakup by Type (in Million USD), 2025-2033
Table 3: Global: Statin Market Forecast: Breakup by Therapeutic Area (in Million USD), 2025-2033
Table 4: Global: Statin Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
Table 5: Global: Statin Market Forecast: Breakup by Application (in Million USD), 2025-2033
Table 6: Global: Statin Market Forecast: Breakup by Distribution (in Million USD), 2025-2033
Table 7: Global: Statin Market Forecast: Breakup by Region (in Million USD), 2025-2033
Table 8: Global: Statin Market: Competitive Structure
Table 9: Global: Statin Market: Key Players

Product Code: SR112025A1885

The global statin market size reached USD 15.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 20.3 Billion by 2033, exhibiting a growth rate (CAGR) of 2.74% during 2025-2033. The market is experiencing steady growth driven by the increasing prevalence of cardiovascular diseases and hypercholesterolemia globally, the expanding healthcare infrastructure and the availability of insurance coverage for cholesterol-lowering medications bolster demand across the globe.

Statin Market Analysis:

Market Growth and Size: The global market is experiencing significant growth, driven largely by the increasing prevalence of cardiovascular diseases. With the rising demand for cholesterol-lowering drugs, the market size is expanding, reflecting a growing awareness and need for effective treatments in managing heart health.
Technological Advancements: Technological developments, particularly in the field of personalized medicine, are revolutionizing the statin market. Advances in genomics and bioinformatics are enabling more personalized treatment approaches, improving the efficacy of statins and reducing the risk of adverse effects, thus catalyzing the market outlook.
Industry Applications: Statins are primarily used in the healthcare industry for the prevention and treatment of cardiovascular diseases by lowering LDL cholesterol levels. Their application has become integral in managing heart health, especially in populations with high risk of heart diseases.
Key Market Trends: A notable trend in the statin market is the shift towards precision medicine, where treatments are tailored to individual genetic profiles. Additionally, there is an increasing focus on preventive healthcare measures, which is driving the demand for statins as a preventive medication for cardiovascular diseases.
Geographical Trends: The demand for statins is particularly high in regions with aging populations and those with prevalent lifestyle-related risk factors for heart diseases. Developed regions such as North America and Europe currently dominate the market, but there is a growing demand in emerging economies due to increasing health awareness and improving healthcare infrastructure.
Competitive Landscape: The global market is characterized by the presence of several key players, with competition driven by innovation, product development, and marketing strategies. The market is also witnessing collaborations between pharmaceutical companies and healthcare providers to enhance the accessibility and effectiveness of statin therapy.
Challenges and Opportunities: One major challenge in the market is addressing the adverse effects associated with statin use, which can affect patient compliance. However, this challenge presents an opportunity for the development of new statin formulations with fewer side effects. Additionally, the increasing incidence of cardiovascular diseases globally offers a substantial opportunity for market expansion.

Statin Market Trends:

Increasing prevalence of cardiovascular diseases

Statin medication with its cholesterol-lowering property serves as a cardiovascular disease (CVD) illness management and prevention treatment. This increasing health cost is, however, leading to an equal growing awareness and management of risk factors such as hypercholesterolemia in a preventive manner. As a result, it is increasing the market for this kind of products. Consequently, the need for statins is increasing phenomenally due to the growing number of patients and the greater focus on preventive health care in general. Among the communities with a rising number of older people and lifestyle-related risk factors for heart diseases, the statins are a significant part of cardiovascular therapies.

Advancements in personalized medicine

Personalized or precision medicine aims at designing a medical treatment to fit to each patient's characteristics by means of genotype examination with regard to the responsiveness to statins. Moreover, the studies have revealed that the genetic variations can alter a person's way to statins both for effectiveness and for risk of side effects. Consequently, there is a growing trend toward handling patients individually, and every time doing so leads to further refinement of statin medication optimization. Apart from aforementioned, joining of genomics and bioinformatics in healthcare is undoubtedly the most critical development that is augmenting the market growth.

Government initiatives and healthcare policies

Government initiatives and health policies extensively govern the international market. Various governments around the world are taking actions through policies and programs for preventing the increasing heart diseases. These programs frequently issue regulations governing cholesterol control, which endorse the use of statins as the initial form of treatment. Additionally, governments as well as healthcare agencies more often than not emphasize the importance of preventative measures, realizing the effectiveness of preventing heart diseases rather than treating them after the occurrence. This shift of attention is causing more investment to be made in information campaigns that highlight the importance of cholesterol control, which in turn is driving the demand for statins. Also, the recommendation of statins in national and international treatment guidelines also indicates the iconic role of these drugs in cardiac health management and confidently boosts their use in clinical practice.

Statin Industry Segmentation:

Breakup by Type:

Synthetic Statins
Natural Statins

Natural statins account for the majority of the market share

The natural statins segment has the largest share of the market. Bio-statins are often considered safer in terms of side effects owing to the fact that they are derived from natural sources. This part includes statins, such as lovastatin which is natural and can be found in the red yeast rice products. The increasing demand for natural statins is associated with the expanding trend of organic and naturally-derived medications, which are preferred by patients with negative experience of side effects of synthetic drugs or those who are scared of synthetic medications. Such commercially sold statins are usually promoted as being easy on the body and being the main reason they are now widely accepted.

On the contrary, synthetic statins which make up a part of the total statin market are medicines that are artificially manufactured for the purpose of reducing cholesterol levels. These statins are known for their potency and superiority in lowering LDL cholesterol, which is recognized to be an important risk factor for cardiovascular diseases. Synthetic statins contain widely-known drugs such as atorvastatin and rosuvastatin. Moreover, the capability of synthetic statins in drastically reducing cholesterol concentration is leading to their universal adoption. They continue to play a significant role in the prevalence of statins due to their high efficacy in maintaining cholesterol levels in patients with a high risk of cardiovascular complications.

Breakup by Therapeutic Area:

Cardiovascular Disorders
Obesity
Inflammatory Disorders
Others

The cardiovascular disorders segment, which is the most significant one among the statins, works by lowering cholesterol levels, which is a crucial risk factor for CVDs. Statins are the most popular medications for prevention of many heart diseases including stroke, coronary artery disease, and heart attack. On the other hand, the increasing global incidence of CVDs has accelerated following the factors such as aging of the population and lifestyle change and thereby the demand for statins in this therapeutic field becomes high.

The use of statins in obesity segment is as the adjunct therapy for the lipid dysfunctions commonly seen in individuals with increased body weight. Developing high cholesterol and as a consequence cardiovascular problems are the most common problems for obese. There is an increasing trend towards statin prescription in conjunction with lifestyle interventions in the wake of rising global obesity, especially in the developed countries and thus the market is increasing due to statins acceptance in comprehensive obesity management strategies.

In addition, the market of the inflammatory disorders segment is moving due to the hypothesis that statins have the capacity of lowering the inflammation, which is mostly caused by the unhealthy diet. Chronic inflammation has been identified as a factor in several conditions, such as some autoimmune diseases, and it is possible that statins may interfere with this inflammatory response. Although this application is less famous than statin's role in the cardiovascular health, the clinical trials and research results could help to improve the role of statins in fighting the inflammatory processes, which could be a potential new growth area for their market in this segment.

Breakup by Drug Class:

Atorvastatin
Fluvastatin
Lovastatin
Pravastatin
Simvastatin
Others

Atorvastatin represents the leading market segment

Atorvastatin holds the largest share in the statin market, primarily due to its efficacy in significantly lowering low-density lipoprotein (LDL) cholesterol. It is widely prescribed for the prevention and treatment of cardiovascular diseases. Atorvastatin's popularity stems from its potent lipid-lowering ability, coupled with a well-established safety profile. In addition, the drug is effective in a range of patient populations, including those with high cardiovascular risk. Its market dominance is also supported by the extensive clinical data underscoring its benefits in reducing the risk of heart attacks and strokes.

On the other hand, fluvastatin, while a smaller segment of the statin market, is recognized for its unique pharmacokinetic properties, making it a suitable option for certain patient groups. It is often prescribed for patients who may be at risk of drug-drug interactions with other statins due to its relatively favorable interaction profile. It is effective in lowering cholesterol levels and is particularly used in patients requiring moderate lipid-lowering effects.

Moreover, lovastatin, a naturally derived statin, has a significant place in the market, especially among patients and healthcare providers favoring naturally sourced medications. While not as potent as some synthetic statins, lovastatin is effective in lowering cholesterol and is often used in patients with mild to moderate hypercholesterolemia. Its market segment benefits from the growing trend towards natural and organic medicinal products.

Additionally, pravastatin is distinguished in the market for its hydrophilic properties, which tend to be associated with a lower risk of muscle-related side effects. This makes pravastatin a preferred choice for patients who may be susceptible to or have a history of statin-induced myopathy. Its effectiveness in lowering cholesterol, combined with a favorable side effect profile, contributes to its steady presence in the market.

Furthermore, simvastatin is another major segment of the statin market, known for its effectiveness and affordability. It is commonly prescribed for cholesterol management and has a long-standing record of reducing the risk of cardiovascular events. Simvastatin's widespread use is also due to its availability in generic form, making it a cost-effective option for many patients.

Breakup by Application:

Dyslipidemia
Others

The dyslipidemia segment forms the cornerstone of the market, given that statins are primarily prescribed for their lipid-lowering properties. Dyslipidemia, characterized by abnormal levels of lipids in the blood, is a major risk factor for cardiovascular diseases. They effectively lower high levels of low-density lipoprotein (LDL) cholesterol and triglycerides, thereby reducing the risk of heart attacks and strokes. Along with this, the widespread prevalence of dyslipidemia, driven by factors such as unhealthy diets, sedentary lifestyles, and genetic predispositions, contributes to the high demand for statins in this segment. The treatment of dyslipidemia with statins is well-established in clinical practice, supported by extensive research validating their efficacy and safety for long-term use.

Breakup by Distribution:

Hospitals
Clinics
Others

Hospitals dominate the market

The hospital segment is the largest in the market, primarily due to the critical role hospitals play in diagnosing and managing cardiovascular diseases and other conditions requiring statin therapy. Hospitals are key centers for the initiation of statin treatment, especially for patients presenting with acute cardiovascular events or those undergoing cardiac procedures. In addition, the availability of a wide range of statin drugs in hospital pharmacies, coupled with the presence of specialized healthcare professionals who can prescribe and monitor statin therapy, makes hospitals a central point for statin distribution. This segment benefits from the established infrastructure of hospitals, which often includes comprehensive cardiac care units and regular follow-up mechanisms, ensuring effective management of patients on statin therapy.

On the contrary, clinics, including private practices and specialty clinics, form a significant segment for the distribution of statins. They cater primarily to the ongoing management of chronic conditions including dyslipidemia and cardiovascular disease prevention. In these settings, statins are prescribed as part of long-term care plans. Clinics are often more accessible than hospitals for regular check-ups and monitoring of lipid levels, making them a convenient option for patients on long-term statin therapy.

Breakup by Region:

North America
- United States
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

North America leads the market, accounting for the largest statin market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The North American region, encompassing the United States and Canada, represents a significant portion of the market. This region's market strength can be supported by a high prevalence of cardiovascular diseases, a well-established healthcare system, and the presence of leading pharmaceutical companies engaged in statin production and research. In addition, the increasing awareness about cholesterol management and preventive healthcare measures, coupled with favorable healthcare policies and reimbursement scenarios, supports the strong demand for statins in North America.

The Asia Pacific region is driven by a rapidly growing patient population with cardiovascular diseases and changing lifestyle patterns. Countries such as China and India, with their large populations and increasing incidence of heart-related health issues, contribute significantly to the market's expansion. The region's growth is further bolstered by improving healthcare infrastructure, rising healthcare expenditure, and growing awareness about cholesterol management. Additionally, the increasing prevalence of lifestyle-related conditions such as obesity and diabetes in the Asia Pacific region contributes to the heightened demand for statins.

Europe's statin market is characterized by advanced healthcare systems, widespread awareness of cardiovascular health, and a large elderly population susceptible to heart diseases. The presence of robust healthcare policies, coupled with extensive research and development activities, drives the demand for statins in this region. European countries exhibit high healthcare spending, which aids in the adoption of effective cholesterol management strategies, including the use of statins.

The Latin American statin market is growing, driven by increasing healthcare access and awareness of cardiovascular diseases in the region. Countries like Brazil and Mexico are experiencing a rise in heart disease prevalence, partly due to urbanization and lifestyle changes. The region's market growth is also supported by improving economic conditions, which allow for better healthcare spending and access to medications, including statins.

The Middle East and Africa region, while smaller in comparison to other regions, is experiencing growth in the market. Factors contributing to this growth include rising awareness of cardiovascular health, increasing incidence of lifestyle-related diseases, and gradual improvements in healthcare infrastructure. The region's market development is, however, challenged by disparities in healthcare access and affordability, particularly in less developed areas.

Leading Key Players in the Statin Industry:

In the market, key players are actively engaged in several strategic initiatives to maintain and enhance their market positions. These initiatives include extensive research and development efforts to formulate innovative hair growth solutions, often incorporating natural ingredients to meet the rising demand for safe and effective products. In addition, companies are investing in robust marketing campaigns to educate consumers about the benefits of their products, utilizing both online and offline channels. In confluence with this, partnerships with dermatologists and hair care professionals are becoming increasingly common to reinforce the credibility of these products. Furthermore, the industry leaders are focused on product innovation, customer education, and collaborations to stay competitive and cater to the growing demand for hair growth solutions.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Abbott Laboratories
AstraZeneca
Aurobindo Pharma
Biocon
GlaxoSmithKline
Merck & Co.
Novartis
Pfizer

Key Questions Answered in This Report

1.What was the size of the global statin market in 2024?
2.What is the expected growth rate of the global statin market during 2025-2033?
3.What are the key factors driving the global statin market?
4.What has been the impact of COVID-19 on the global statin market?
5.What is the breakup of the global statin market based on the type?
6.What is the breakup of the global statin market based on the drug class?
7.What is the breakup of the global statin market based on the distribution?
8.What are the key regions in the global statin market?
9.Who are the key players/companies in the global statin market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Statin Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Type

6.1 Synthetic Statins
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Natural Statins
- 6.2.1 Market Trends
- 6.2.2 Market Forecast

7 Market Breakup by Therapeutic Area

7.1 Cardiovascular Disorders
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Obesity
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Inflammatory Disorders
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast

8 Market Breakup by Drug Class

8.1 Atorvastatin
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Fluvastatin
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Lovastatin
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Pravastatin
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
8.5 Simvastatin
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
8.6 Others
- 8.6.1 Market Trends
- 8.6.2 Market Forecast

9 Market Breakup by Application

9.1 Dyslipidemia
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Others
- 9.2.1 Market Trends
- 9.2.2 Market Forecast

10 Market Breakup by Distribution

10.1 Hospitals
- 10.1.1 Market Trends
- 10.1.2 Market Forecast
10.2 Clinics
- 10.2.1 Market Trends
- 10.2.2 Market Forecast
10.3 Others
- 10.3.1 Market Trends
- 10.3.2 Market Forecast

11 Market Breakup by Region

11.1 North America
- 11.1.1 United States
  - 11.1.1.1 Market Trends
  - 11.1.1.2 Market Forecast
- 11.1.2 Canada
  - 11.1.2.1 Market Trends
  - 11.1.2.2 Market Forecast
11.2 Europe
- 11.2.1 Germany
  - 11.2.1.1 Market Trends
  - 11.2.1.2 Market Forecast
- 11.2.2 France
  - 11.2.2.1 Market Trends
  - 11.2.2.2 Market Forecast
- 11.2.3 United Kingdom
  - 11.2.3.1 Market Trends
  - 11.2.3.2 Market Forecast
- 11.2.4 Italy
  - 11.2.4.1 Market Trends
  - 11.2.4.2 Market Forecast
- 11.2.5 Spain
  - 11.2.5.1 Market Trends
  - 11.2.5.2 Market Forecast
- 11.2.6 Russia
  - 11.2.6.1 Market Trends
  - 11.2.6.2 Market Forecast
- 11.2.7 Others
  - 11.2.7.1 Market Trends
  - 11.2.7.2 Market Forecast
11.3 Asia Pacific
- 11.3.1 China
  - 11.3.1.1 Market Trends
  - 11.3.1.2 Market Forecast
- 11.3.2 Japan
  - 11.3.2.1 Market Trends
  - 11.3.2.2 Market Forecast
- 11.3.3 India
  - 11.3.3.1 Market Trends
  - 11.3.3.2 Market Forecast
- 11.3.4 South Korea
  - 11.3.4.1 Market Trends
  - 11.3.4.2 Market Forecast
- 11.3.5 Australia
  - 11.3.5.1 Market Trends
  - 11.3.5.2 Market Forecast
- 11.3.6 Indonesia
  - 11.3.6.1 Market Trends
  - 11.3.6.2 Market Forecast
- 11.3.7 Others
  - 11.3.7.1 Market Trends
  - 11.3.7.2 Market Forecast
11.4 Latin America
- 11.4.1 Brazil
  - 11.4.1.1 Market Trends
  - 11.4.1.2 Market Forecast
- 11.4.2 Mexico
  - 11.4.2.1 Market Trends
  - 11.4.2.2 Market Forecast
- 11.4.3 Others
  - 11.4.3.1 Market Trends
  - 11.4.3.2 Market Forecast
11.5 Middle East and Africa
- 11.5.1 Market Trends
- 11.5.2 Market Breakup by Country
- 11.5.3 Market Forecast

12 SWOT Analysis

12.1 Overview
12.2 Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

14.1 Overview
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Degree of Competition
14.5 Threat of New Entrants
14.6 Threat of Substitutes

15 Price Indicators

16 Competitive Landscape

16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
- 16.3.1 Abbott
  - 16.3.1.1 Company Overview
  - 16.3.1.2 Product Portfolio
  - 16.3.1.3 Financials
  - 16.3.1.4 SWOT Analysis
- 16.3.2 AstraZeneca
  - 16.3.2.1 Company Overview
  - 16.3.2.2 Product Portfolio
  - 16.3.2.3 Financials
  - 16.3.2.4 SWOT Analysis
- 16.3.3 Aurobindo Pharma
  - 16.3.3.1 Company Overview
  - 16.3.3.2 Product Portfolio
  - 16.3.3.3 Financials
- 16.3.4 Biocon
  - 16.3.4.1 Company Overview
  - 16.3.4.2 Product Portfolio
  - 16.3.4.3 Financials
  - 16.3.4.4 SWOT Analysis
- 16.3.5 GlaxoSmithKline
  - 16.3.5.1 Company Overview
  - 16.3.5.2 Product Portfolio
  - 16.3.5.3 Financials
  - 16.3.5.4 SWOT Analysis
- 16.3.6 Merck & Co.
  - 16.3.6.1 Company Overview
  - 16.3.6.2 Product Portfolio
  - 16.3.6.3 Financials
  - 16.3.6.4 SWOT Analysis
- 16.3.7 Novartis
  - 16.3.7.1 Company Overview
  - 16.3.7.2 Product Portfolio
  - 16.3.7.3 Financials
  - 16.3.7.4 SWOT Analysis
- 16.3.8 Pfizer
  - 16.3.8.1 Company Overview
  - 16.3.8.2 Product Portfolio
  - 16.3.8.3 Financials
  - 16.3.8.4 SWOT Analysis

スタチン市場レポート：タイプ別、治療領域別、薬剤クラス別、用途別、流通別、地域別、2025～2033年

Statin Market Report by Type, Therapeutic Area, Drug Class, Application, Distribution, and Region 2025-2033

スタチン市場分析

スタチン市場の動向

目次

第1章 序文

第2章 調査範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界のスタチン市場

第6章 市場内訳：タイプ別

第7章 市場内訳：治療領域別

第8章 市場内訳：薬剤クラス別

第9章 市場内訳：用途別

第10章 市場内訳：流通別

第11章 市場内訳：地域別

第12章 SWOT分析

第13章 バリューチェーン分析

第14章 ポーターのファイブフォース分析

第15章 価格指標

第16章 競合情勢